No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 4.3x · 10Y median 4.3x · 47th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:53:11.742Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T17:53:11.742Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T17:53:11.742Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T17:53:11.742Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:53:11.742Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T17:53:11.742Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:53:11.742Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:53:11.742Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Sotera Health Company (SHC) stock was $18.38 as of Oct 6, 2026, 1:50 PM EDT, down 0.89% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +16.2% · 3-year avg +8.9%/yr · 5-year avg -6.4%/yr
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing.
Medical - Diagnostics & Research · Broadview Heights, OH
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
0.27
Revenue Est.
$319.84M
Last Quarter Results
EPS
$0.26
vs Estimate
$0.24
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SHC | $5.24B | $18.38 | -0.89% | +16.22% | -6.39% | N/A | N/A |
| 2CRSP | $5.25B | $54.38 | -5.16% | -15.29% | -10.97% | N/A | vs SHC |
| 3DOCS | $5.28B | $28.24 | -1.19% | -60.81% | -18.23% | N/A | vs SHC |
| 4PTCT | $5.31B | $63.63 | -0.04% | -2.62% | +11.75% | +16.60% | vs SHC |
| 5COGT | $5.17B | $30.27 | -1.96% | +95.25% | +28.51% | N/A | vs SHC |
| 6TVTX | $5.15B | $55.42 | -3.90% | +133.10% | +17.83% | +9.57% | vs SHC |
7.88
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$321.38M
vs Estimate
$309.70M
Consensus Rating
Based on 9 analysts
Average Price Target
$22.72
+23.6% upside
Low
$18.00
Current
$18.38
High
$25.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.27 | $0.27 | $0.27 | 6 |
| Quarter ending Dec 2026 | $0.27 | $0.28 | $0.29 | 6 |
| Quarter ending Mar 2027 | $0.20 | $0.20 | $0.20 | 2 |
| Quarter ending Jun 2027 | $0.28 | $0.28 | $0.29 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.98 | $0.98 | $0.99 | 5 |
| FY 2027 | $1.06 | $1.07 | $1.09 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $319.00M | $319.84M | $321.49M | 6 |
| Quarter ending Dec 2026 | $323.99M | $325.60M | $326.72M | 6 |
| Quarter ending Mar 2027 | $294.18M | $296.10M | $298.09M | 3 |
| Quarter ending Jun 2027 | $338.11M | $340.31M | $342.59M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.24B | $1.25B | $1.25B | 7 |
| FY 2027 | $1.31B | $1.32B | $1.33B | 7 |
